December 5, 2022 - In early clinical trials, a drug known as FX-322 produced significant improvement in speech perception in several participants with noise-induced hearing loss after a single injection into the inner ear -- with some reporting benefits that lasted as long as two years, according to its developer, ...

November 17, 2022 - At the event, Company management will review the FX-322-208 study design, the patient populations targeted for enrollment, pre-specified speech perception endpoints, and the potential FX-322 commercial market opportunity. Key opinion leaders (KOLs) in auditory science and otolaryngology will ...

With data from all of our single administration studies, we have been able to better define the groups of patients that we believe are responding to FX-322, while also informing the optimal study design for new placebo-controlled Phase 2 trials,” said David L.

July 10, 2022 - FX-322 helps renew only the cochlea's very high-frequency hair cells. Because FX-345 is designed to penetrate much deeper into the cochlea, it may stimulate progenitor cells at much lower frequency ranges. As exciting as this all sounds, we'll have to wait for the results of clinical trials ...

August 7, 2024 - Frequency Therapeutics is currently conducting a Phase 2b trial to see if a new drug candidate can restore hearing in people who experience sensorineural hearing loss (SNHL).

July 18, 2019 - Woburn-based Frequency Therapeutics has entered into an exclusive license agreement with Tokyo’s Astellas Pharma to develop and commercialize Frequency’s regenerative therapeutic candidate, FX-322, for the treatment of sensorineural hearing loss, the most common type of hearing loss.

November 10, 2021 - On Tuesday, the company made several announcements regarding its FX-322 — its drug candidate for hearing loss. Frequency highlighted pooled data from early trials suggesting the product has lead to clinical benefits, and suggested that a Phase 2 study’s discouraging results were due to ...

September 7, 2021 - Previously, renowned researchers Bob Langer and Jeff Karp conceived the idea of utilizing small molecules to activate and differentiate stem cells to proliferate the growth of sensory cells. The idea was successfully transformed into a real therapeutics FX-322 to treat SNHL by Massachusetts-based ...

September 14, 2020 - The drug, called FX-322, is a combination of two molecules that affect specialized cells called progenitor cells in the inner ear. These cells are the source of ear sensory hair cells, but they lie dormant once the ear is finished developing. One molecule in FX-322 acts like the ignition key ...

April 22, 2021 - These are among the pleasing sounds that Hertz Fellow Chris Loose hopes to restore to the hearing impaired. Loose’s company, Frequency Therapeutics, last year tested a combination therapy of two small molecules (FX-322) on patients with mild to moderately severe hearing loss. Multiple people […]

Eligibility: Participants must be between 18-65 years old with an established diagnosis of stable sensorineural hearing loss by standard hearing tests. Goal: To evaluate a new investigational medication called FX-322 that is delivered directly in the ear through the eardrum.